The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Letter to the Editor
Editor, – The article 'Thiazolidinediones - mechanisms of action' (Aust Prescr 2004;27:67-70), states that 'hepatotoxicity does not seem to be associated with the other two compounds (pioglitazone, rosiglitazone)'. Although admittedly this may be referring to the rare but fatal cases of hepatotoxicity associated with troglitazone, it does seem somewhat at odds with the ADRAC Bulletin. This reported on 16 cases of hepatic adverse reactions including elevated liver function tests, jaundice, hepatitis and hepatocellular damage. Although it does add the rider that 'liver enzyme levels may be elevated with diabetes or obesity'.1
Bunbury Regional Hospital
- ADRAC. The glitazones - early experience. Aust Adv Drug React Bull 2003;22:6-7.
- Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annu Rev Med 2001;52:239-57.
- Tolman KG, Chandramouli J. Hepatotoxicity of the thiazolidinediones. Clin Liver Dis 2003;7:369-79.
- Freid J, Everitt D, Boscia J. Rosiglitazone and hepatic failure. Ann Intern Med 2000;132:164.
- Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004;5:27-42.